Radiation therapy for breast cancer can weaken the bones it passes through, most commonly the ribs, sternum, and clavicle on the treated side. The effects range from subtle losses in bone density to rib fractures that show up months or years later, and in rare cases, a condition called osteoradionecrosis where irradiated bone progressively deteriorates. Most of these complications are uncommon with modern treatment techniques, but understanding the risks helps you and your care team monitor the right things during follow-up.
How Radiation Damages Bone Tissue
Bone is living tissue constantly being remodeled by two types of cells working in balance: one type breaks down old bone, and the other builds new bone to replace it. High-dose radiation, the kind used to treat cancer, disrupts both cell types but hits the bone-building cells especially hard. The result is that bone gets broken down faster than it can be rebuilt, leading to net bone loss in the irradiated area. The effects depend heavily on the total dose delivered and how it is spread over treatment sessions.
Animal studies help illustrate the scale of this damage. In one study using mice, fractionated radiation (multiple smaller doses over time, mimicking a typical breast cancer treatment schedule) caused bone mineral density losses of roughly 19% to 23% in the femur and reduced the amount of internal spongy bone by about 38%. These losses were greater than those caused by a single large dose, and the fractionated-dose group also showed significantly weaker bones when tested for resistance to fracture.
1PubMed Central. Effects of Radiotherapy Upon Bone Structure-Strength Relationships Vary With Sex and Fractionation of DosingThese are animal findings and the numbers do not translate directly to humans, but the pattern matters: the way radiation is delivered, not just how much, influences the degree of bone damage. This is one reason radiation oncologists carefully plan treatment fields to limit how much healthy bone receives high doses.
Rib Fractures After Breast Radiation
The ribs sitting just beneath the breast tissue are the bones most directly in the radiation path, and rib fracture is the most studied bone complication after breast radiation. In a study of patients treated with proton therapy, the three-year rate of rib fractures within the radiation field was about 3.7%. That sounds alarming at first, but there is an important detail: only one of the eight patients who developed fractures actually had symptoms. The rest were discovered incidentally on routine follow-up imaging, giving a symptomatic fracture rate of just 0.4%.
2PubMed Central. Incidence of Rib Fracture following Treatment with Proton Therapy for Breast CancerWhat’s notable is that the study found no patient characteristics that predicted who would develop a fracture. Age, race, whether someone was taking an aromatase inhibitor, calcium or vitamin D supplementation, and even whether they had been diagnosed with vitamin D deficiency before treatment all showed no statistically significant link to fracture risk. A separate analysis of proton therapy patients found that fractures typically appeared about 12 months after treatment ended, with a range of 5 to 14 months.
3PubMed Central. Study of linear energy transfer effect on rib fracture in breast cancer patients receiving pencil-beam-scanning proton therapyThree patients in the larger proton therapy study also developed rib fractures outside the radiation field entirely, at a rate of about 0.9%. That is a useful comparison point: it suggests that some fractures in breast cancer patients would happen regardless of radiation, perhaps from the general bone-health impacts of cancer treatment or from age and osteoporosis risk factors that already existed.
2PubMed Central. Incidence of Rib Fracture following Treatment with Proton Therapy for Breast CancerOsteoradionecrosis
At the more serious end of the spectrum is osteoradionecrosis, where irradiated bone loses its blood supply and progressively dies. Radiation causes fibrosis (scarring) in surrounding soft tissue and blocks the tiny arteries that feed bone, leaving it starved of oxygen and unable to heal normally. Over time, this can lead to bone that is fragile, infected, or collapses on its own. The condition can show up as persistent pain, chronic infection, or a fracture that does not heal the way you would expect.
4CMAJ. Osteoradionecrosis secondary to breast reirradiationOsteoradionecrosis is associated with cumulative radiation doses above roughly 60 Gray (a measure of radiation dose), and other risk factors include infection, inflammation, and how close the tumor sits to bone. In a reported case after breast radiation, a patient developed fractures of two ribs about 11 months after treatment, along with bone marrow changes visible on MRI across several additional ribs.
5PubMed Central. Osteoradionecrosis of the Ribs following Breast RadiotherapyPeople with certain autoimmune conditions may face higher risk. In one documented case, a patient with lupus developed osteoradionecrosis two years after breast radiation, and the damage progressed over the next 12 years to involve the clavicle, sternum, and rib cage. Multiple reconstructive surgeries were complicated by further tissue breakdown, illustrating how the condition can spiral in susceptible individuals.
6International Journal of Radiation Oncology*Biology*Physics. Consequences of breast irradiation in patients with pre-existing collagen vascular diseasesIt is worth emphasizing that osteoradionecrosis is rare. Standard breast cancer radiation courses typically deliver doses well below the 60 Gray threshold most associated with the condition. The risk climbs meaningfully when someone needs a second course of radiation to the same area, or when treatment involves unusually high total doses.
4CMAJ. Osteoradionecrosis secondary to breast reirradiationChest Wall Pain as a Late Effect
Even without a frank fracture, many women experience chest wall pain after breast radiation, and it is fair to wonder whether this discomfort reflects underlying bone changes. A systematic review pooling data from several thousand patients estimated the overall prevalence of chest wall pain after breast radiation at about 34%. Most of that was mild: roughly 26% of patients reported mild pain. The rate of moderate or severe chest wall pain was considerably lower, at about 5.7%.
7Technical Innovations & Patient Support in Radiation Oncology. Chest wall pain as a late effect following radiotherapy for breast cancer: A systematic review of prevalence and risk factorsChest wall pain after radiation does not always mean something is wrong with the bone. It can come from skin changes, muscle tightness, nerve irritation, or scar tissue forming within the chest wall. But the fact that about a third of patients experience it to some degree means it is a question worth raising with your oncologist during survivorship visits, especially if the pain is new, worsening, or in a very specific spot. A localized pain that lines up with a rib in the radiation field may warrant imaging to rule out a stress fracture or early bone damage.
When Bone Changes Look Like Cancer Returning
One of the more stressful aspects of post-treatment bone complications is that they can look disturbingly like metastatic disease on imaging. A rib fracture caused by radiation can show increased activity on a bone scan, and marrow changes from radiation damage can mimic the appearance of cancer that has spread to bone on MRI. This creates real diagnostic challenges for both patients and their doctors.
5PubMed Central. Osteoradionecrosis of the Ribs following Breast RadiotherapyRadiation-induced bone injuries, insufficiency fractures, and osteoradionecrosis can all closely mimic metastatic bone disease or infection on imaging, and the overlap in appearances is a recognized diagnostic pitfall.
4CMAJ. Osteoradionecrosis secondary to breast reirradiationIf you are a breast cancer survivor and a follow-up scan flags something suspicious in a bone that was in or near the radiation field, do not panic immediately. Your doctors should consider the location of the finding relative to the radiation field, the time since treatment, and your overall clinical picture. Often, additional imaging or a biopsy can clarify whether the finding represents radiation damage or something more concerning. Knowing that radiation-related bone changes exist and can mimic metastasis helps set realistic expectations for what follow-up imaging may occasionally turn up.
The Bigger Bone Problem Often Is Not Radiation Itself
Radiation treats one area and affects the bones in its path. But many breast cancer patients face a broader, systemic threat to their skeleton from other parts of treatment. Chemotherapy and hormonal therapies are frequent culprits, and in terms of overall bone loss across the entire skeleton, they tend to be a bigger concern than radiation.
Chemotherapy regimens can push premenopausal women into early menopause by shutting down ovarian function. Estrogen plays a major role in maintaining bone density, and losing it abruptly leads to rapid bone loss. A study of premenopausal women who stopped menstruating after chemotherapy found they lost 9.5% of their lumbar spine bone density and 4.6% at the femoral neck (hip) within two years. Women whose periods continued had only minimal changes.
8PubMed. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patientsFor postmenopausal women, aromatase inhibitors, a standard hormonal therapy for hormone-receptor-positive breast cancer, work by blocking the body’s remaining estrogen production. This is effective against cancer recurrence but accelerates bone thinning. Research has documented a high prevalence of vertebral fractures in women starting aromatase inhibitor therapy.
9Annals of Oncology. High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapyThe practical takeaway is that if you are being treated for breast cancer, bone health is worth paying attention to from the start of treatment, not just because of radiation’s local effects but because chemotherapy-induced menopause or years on an aromatase inhibitor can thin bones everywhere. A baseline bone density scan near the start of treatment gives your team a reference point to track changes over time.
Medications That Protect Against Bone Loss
Several drugs can slow or reverse the bone loss associated with breast cancer treatment. Bisphosphonates like zoledronic acid, alendronate, and risedronate are commonly used, and denosumab is specifically approved for building bone mass in women at high fracture risk from aromatase inhibitor treatment. Data from a large phase III trial found that denosumab improved bone density and cut clinical fractures in half, with measurable gains at the spine, hip, and forearm.
10PubMed Central. Cancer Treatment-Induced Bone Loss: Role of Denosumab in Non-Metastatic Breast CancerIn the chemotherapy-induced bone loss study mentioned earlier, the bisphosphonate clodronate significantly reduced the rate of bone loss in women who had gone into chemotherapy-induced menopause. At two years, lumbar spine loss was cut from 9.5% to 5.9%, and femoral neck loss went from 4.6% to just 0.4%.
8PubMed. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patientsNot every breast cancer patient needs bone-protective medication. The decision depends on factors like your fracture risk, whether you are pre- or postmenopausal, which treatments you are receiving, and your baseline bone density. But if you are on an aromatase inhibitor or experienced chemotherapy-induced menopause, it is a conversation worth having with your oncologist. These medications are well-studied and can make a meaningful difference over several years of treatment.
What About Exercise?
Exercise is often recommended for general health during and after cancer treatment, and it is natural to wonder whether it can protect your bones too. The evidence here is mixed and depends on your menopausal status. A systematic review of exercise studies in breast cancer patients found that in postmenopausal women, exercise programs did not preserve bone density at any measured site after one year. However, in premenopausal women, one large trial found that exercise reduced bone loss at the hip (femoral neck), though it did not help at the spine.
11PubMed. Exercise for improving bone health in women treated for stages I-III breast cancer: a systematic review and meta-analysesThis does not mean postmenopausal women should skip exercise. Physical activity still helps with fatigue, cardiovascular health, balance (which reduces fall risk and therefore fracture risk), and quality of life. The evidence simply suggests that exercise alone is not enough to counteract the bone loss driven by estrogen depletion. Medications remain the more effective tool for that specific problem, with exercise serving as a complement rather than a substitute.
Blood Tests That May Flag Bone Damage Early
One area of active research is whether blood tests can detect radiation-induced bone damage before it shows up on imaging. A study of women treated with pelvic radiation for rectal cancer (a different treatment site, but the same biological process of radiation injuring bone) tracked several bone turnover markers in the blood. In women who went on to develop radiation-induced bone injuries, levels of markers reflecting both bone breakdown and bone formation rose significantly during the first year after treatment. Women who did not develop bone injuries showed stable levels of the same markers.
12PubMed Central. Bone turnover biomarkers reflect radiation-induced bone injuries in women with non-metastatic rectal cancerThis is not yet standard practice for breast cancer patients, and the study population was women with rectal cancer receiving pelvic radiation rather than chest wall radiation. But the principle is biologically plausible: if radiation is actively damaging bone, the chemical byproducts of that damage should be detectable in blood. If validated in breast cancer-specific studies, such markers could eventually help identify patients who need closer monitoring or earlier intervention, rather than waiting for a fracture to appear on a scan months or years down the line. For now, the finding is a signal that the field is moving toward more proactive detection rather than relying solely on imaging after symptoms develop.